Hepatitis B Seroprevalence in the Pediatric and Adolescent Population of Florence (Italy): An Update 27 Years after the Implementation of Universal Vaccination.
hepatitis B, vaccination, seroprevalence, ELISA test, Italy
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
30 Mar 2020
30 Mar 2020
Historique:
received:
05
03
2020
revised:
25
03
2020
accepted:
26
03
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
3
4
2020
Statut:
epublish
Résumé
Hepatitis B still represents a health concern, although safe and effectivevaccines have been available since 1982. Italy introduced a program of universal vaccination againsthepatitis B in 1991. The aim of this study was to assess the immunity levels towards hepatitis B in asample of sera from the pediatric and adolescent population in the province of Florence, CentralItaly, twenty-seven years after the implementation of universal vaccination. A total of 165sera samples were collected from the resident population of Florence aged 1-18 years. The anti-HBsand anti-HBc enzyme-linked immunosorbent Assay (ELISA) tests were performed on all samples.The anamnestic and vaccination status data were also collected. Seroprevalence of anti-HBswas approximately 60%, with children aged 1-5 years having the highest positivity rate (81.6%),and decreasing trends in the older age groups. The zero prevalence of anti-HBc shows that thedetected protective immunity is mainly due to vaccination, and natural infection was not reportedin the studied population. The seroprevalence of anti-HBs and the lack of anti-HBc inthis study highlights that immunity levels have been derived mainly from immunization. Thisconfirms how vaccination dramatically reduced circulation of the hepatitis B virus in Italy in thepediatric and adolescent population twenty-seven years after implementation of the mandatoryuniversal program.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B still represents a health concern, although safe and effectivevaccines have been available since 1982. Italy introduced a program of universal vaccination againsthepatitis B in 1991. The aim of this study was to assess the immunity levels towards hepatitis B in asample of sera from the pediatric and adolescent population in the province of Florence, CentralItaly, twenty-seven years after the implementation of universal vaccination.
METHODS
METHODS
A total of 165sera samples were collected from the resident population of Florence aged 1-18 years. The anti-HBsand anti-HBc enzyme-linked immunosorbent Assay (ELISA) tests were performed on all samples.The anamnestic and vaccination status data were also collected.
RESULTS
RESULTS
Seroprevalence of anti-HBswas approximately 60%, with children aged 1-5 years having the highest positivity rate (81.6%),and decreasing trends in the older age groups. The zero prevalence of anti-HBc shows that thedetected protective immunity is mainly due to vaccination, and natural infection was not reportedin the studied population.
CONCLUSIONS
CONCLUSIONS
The seroprevalence of anti-HBs and the lack of anti-HBc inthis study highlights that immunity levels have been derived mainly from immunization. Thisconfirms how vaccination dramatically reduced circulation of the hepatitis B virus in Italy in thepediatric and adolescent population twenty-seven years after implementation of the mandatoryuniversal program.
Identifiants
pubmed: 32235670
pii: vaccines8020156
doi: 10.3390/vaccines8020156
pmc: PMC7348992
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Epidemiol Infect. 2007 May;135(4):555-62
pubmed: 17076939
Vaccine. 2013 Jan 11;31(4):584-90
pubmed: 23142301
Lancet Infect Dis. 2010 Nov;10(11):755-61
pubmed: 20884297
Patient Prefer Adherence. 2013 Sep 27;7:981-6
pubmed: 24101865
Epidemiol Infect. 2001 Jun;126(3):433-40
pubmed: 11467800
BMC Infect Dis. 2018 Jan 11;18(1):34
pubmed: 29325525
BMC Infect Dis. 2010 Jan 15;10:9
pubmed: 20078876
J Prev Med Hyg. 2011 Jun;52(2):45-6
pubmed: 21842704
Hum Vaccin. 2009 Sep;5(9):592-8
pubmed: 19535920
Epidemiol Infect. 2001 Apr;126(2):249-59
pubmed: 11349976
Epidemiol Infect. 2002 Dec;129(3):543-50
pubmed: 12558337
Lancet. 1990 Jan 20;335(8682):173-4
pubmed: 1967468
J Viral Hepat. 2003 Jan;10(1):1-6
pubmed: 12558904
Vaccine. 2003 Jan 30;21(7-8):685-91
pubmed: 12531340
Epidemiol Infect. 2000 Oct;125(2):347-57
pubmed: 11117958
Vaccine. 1996 Aug;14(11):1019-27
pubmed: 8879096
Vaccine. 2008 Aug 12;26(34):4403-9
pubmed: 18585420
Vaccine. 1999 Aug 20;18(1-2):57-67
pubmed: 10501235
J Infect Dis. 2016 Jul 1;214(1):1-3
pubmed: 26802140
Vaccines (Basel). 2019 Dec 19;8(1):
pubmed: 31861551
Clin Gastroenterol Hepatol. 2004 Oct;2(10):941-5
pubmed: 15476159
Vaccine. 2019 Jan 7;37(2):223-225
pubmed: 28743487
Pediatr Infect Dis J. 2004 Jul;23(7):650-5
pubmed: 15247604
Hum Vaccin Immunother. 2015;11(1):236-9
pubmed: 25483542
Epidemiol Prev. 2014 Nov-Dec;38(6 Suppl 2):57-61
pubmed: 25759345
BMC Public Health. 2008 Oct 27;8:372
pubmed: 18954432
Hum Vaccin Immunother. 2013 Mar;9(3):636-41
pubmed: 23354158
BMC Infect Dis. 2008 Jul 28;8:100
pubmed: 18662386
Vaccine. 2007 Sep 28;25(39-40):6958-64
pubmed: 17714836